WAF1/CIP1 may act as a tumour suppressor gene (TSG) and loss of the p21 WAF1/CIP1 gene has been reported in several solid tumours. The aim of this study was to see whether p21
Introduction
Progression through the G1/S checkpoint of the cell cycle is regulated by a family of cyclin-dependent kinases (CDKs), whose activity is in turn controlled by CDK inhibitors (CDKIs), including p21 WAF1/CIP1 . p21
was identified simultaneously as a mediator of p53-induced growth arrest (wild-type p53-activated fragment 1) 1 and as a regulator of CDK (CDK-interacting protein). 2 Factors including TGF-b, 3 IFN-a, IFN-b, IFN-g, [4] [5] [6] IL-6 7 and EGF, 8 have been shown to upregulate p21
via the JAK-STAT and other pathways, in a p53-independent manner. 6 p21 WAF1/CIP1 also inhibits DNA replication directly, by binding to the proliferating nuclear antigen (PCNA), a subunit of DNA polymerase d. 9, 10 In addition to its associations with CDKs and PCNA, p21 WAF1/CIP1 participates in specific protein-toprotein interactions, acting both on other cell cycle regulators and as a modulator of apoptosis. 11 Malignancy is characterised by the inability of cells to respond correctly to growth arrest signals. The various roles of p21 WAF1/CIP1 and other CDKIs as inhibitors of the cell cycle and as a modulators of apoptosis and differentiation implies a tumour suppressor function. 12, 13 Decreased levels of CDKIs, or increased cyclin-CDK levels, may lead to inappropriate cell division. Alternatively, decreased levels of CDKIs may limit the cellular response to DNA damage.
Lack of p21
WAF1/CIP1 gene expression has been related to poor prognosis in several solid cancers including pancreatic, 14 gastric, 15 bladder 16 and non-small-cell lung cancers. 17 Immunohistochemical studies have shown reduced p21 WAF1/CIP1 protein expression in prostate cancer can be used to predict poor survival outcome. 18, 19 Although decreased p21 WAF1/CIP1 expression is often detected in cancer cells, the mechanism of inactivation is not known, mutations and allelic loss of p21 WAF1/CIP1 are rarely found. 6, 20 In acute lymphoblastic leukaemia poor prognosis is associated with transcriptional silencing of the p21 WAF1/CIP1 gene, in this instance decreased expression occurs by methylation of the CpG islands in the promoter region.
21
DNA methylation involves the addition of a methyl group to the carbon-5 position of cytosine residues, and occurs almost exclusively at cytosine residues that are immediately followed by guanine (CpG dinucleotides). Isolated CpG dinucleotides are relatively rare and are nearly always methylated. In contrast, small stretches of DNA rich in CpG dinucleotides, the CpG islands, are usually free of methylation. These CpG islands are frequently found in the promoter region of human genes and methylation within the islands has been associated with transcriptional inactivation of the corresponding gene. Alteration in DNA methylation in the promoter region of tumour suppressor genes (TSGs) may be pivotal to the development of cancer. 22 The aim of this study was to examine p21 WAF1/CIP1 expression in metastatic prostate cancer cell lines and to assess the methylation status of the promoter region.
Materials and methods

Cell culture and treatment
Human metastatic prostate cancer cell lines PC3, LNCaP, DU145 and 1542 NP a normal prostate epithelial cell line, were obtained from the originators, RD a rhabdomyosarcoma cell line was obtained from ATCC. LNCaP cells have a slower replication rate than the other cells lines. In all, 500 000 PC3, DU145, 1542NP, RD cells and 10 6 cell LNCaP cell were plated in T80 flasks containing RPMI-1640 (Gibco BRL), 10% foetal calf serum (FCS) and 1% of L-glutamine (G). After 16 h, 500 nM of the demethylating agent 5-Aza-2 deoxycytidine (5-Aza-CdR) (Sigma Chemical Co: A 3656 C 8 H 12 N 4 O 4 ) in 15 ml of phosphate buffer solution (PBS) was added to the test flasks and 15 ml PBS was added to the control flasks. 5-Aza-CdR sequesters the enzyme DNA methyltransferase and thus prevents DNA methylation during replication. Following treatment for 24 h the test and control media was replaced with standard growth medium (RPMI-1640, FCS, G). After 5 days the cells were harvested, snap frozen and stored at À801C. Cell culture was performed in triplicate.
RNA from cell lines was extracted using RNeasy s mini kits (QIAGEN s ), according to the manufacturer's instructions. In all, 1 mg total cellular RNA was reverse transcribed using oligodT primers and SuperScript II reverse transcriptase (RT) (QIAGEN s ). cDNA was amplified using intragenic primers at p21 (Table 1) , spanning a region À990 to À67 relative to the transcription start site and to the glyceraldehyde phosphate dehydrogenase gene (GAPDH). Reactions were performed in a Perkin Elmer-Gene Amp 2400 thermal cycler (Perkin Elmer Ltd, UK), at 941C for 150 s, then 34 cycles at 941C for 45 s, 601C for 45 s and 721C for 45 s, followed by an extension step at 721C for 5 min. The PCR products were electrophoresed through a 1.5% agarose gel, DNA extraction was performed using the DNeasy Tissue kit s according to the manufacturer's protocol. The CgGenomet DNA modification kit (Intergen) was used to treat 1 mg of DNA extracted from PC3, LNCaP, DU145, RD, 1542NP cell lines with sodium bisulphite (modified DNA). Sodium bisulphite deaminates cytosine, removing the NH 2 group from carbon-4 and converting cytosine to uracil, unless the cytosine is methylated in the carbon-5 position. During PCR amplification uracil binds adenine and adenine binds thymine. Consequently, following bisulphite modification an unmethylated cytosine will sequence as thymine and a methylated cytosine will sequence as cytosine.
Primers were designed to yield product containing the CpG islands of the promoter region, as methylation at these sites may be associated with transcriptional inactivation. CpG sites were not included in the primer sequence as this repeating sequence would reduce the specificity of primer annealing. As CpG sites were not included in the sequence, primers were designed for DNA in which all cytosine were converted to uracil by modification with sodium bisulphite, these were termed modification primers (M). Primers were also designed at the same sites for untreated DNA, named unmodified (U) primers, these were used as a control. Sense and antisense primers for the modified (M1 and M2) and unmodified (U1) promoter region of p21 WAF1/CIP1 including the Sis-inducible element (SIE)-1 STAT-binding site at À692, are shown in Table 2 . Sense and antisense primers were used as the PCR products had long sequences. The PCR protocol was 951C for 150 s, then PCR product was electrophoresed on a 1.5% agarose gel and extracted using a QIAquick Gel Extraction Kit s (QIAGEN). The PCR products were sequenced directly using both sense and antisense primers by cycle sequencing (Amplitaq DNA polymerase ABI) and were analysed using a on the ABI PRISM s 377 DNA Sequencer.
Results
RT-PCR was performed on cDNA derived in triplicate from RNA of the 5-Aza-CdR-treated and -untreated cell lines. In all three prostate cancer cell lines p21 gene in RD has previously been shown to be inactivated by promoter methylation 23 and was included as a positive control for methylation-sensitive expression. In the untreated RD cell line p21 WAF1/CIP1 was expressed at a low level, following 5-Aza-CdR treatment gene expression increased (Figure 1a ). 1542NP cells expressed p21 WAF1/CIP1 before and after treatment with 5-AzaCdR. The GAPDH control confirmed equivalent quantities of cDNA in the treated and untreated pairs (Figure 1b) . Figure 2 demonstrates treatment with 5-Aza-CdR has a profound effect on the rate of cell division. The rate of cell turnover was 1.9 Â in PC3, 1.8 Â in LNCaP, 1.3 Â in DU145 and 21 Â in RD greater in the untreated cells. WAF1/CIP1 gene in prostalic cancer SRJ Bott et al These findings suggest the p21 WAF1/CIP1 gene is inactivated by methylation in prostate cancer. To provide further evidence that inactivation of p21 in the prostate cancer cell lines was due to methylation in the promoter, cell line DNA was modified by sodium bisulphite treatment and sequenced. In all three prostate cancer cell lines (PC3, LNCaP, DU145) cytosine was conserved following sodium bisulphite treatment at positions À896, À856 and À692 in the p21 promoter, confirming methylation at these sites ( Figure 3 ). In the RD cell line, a positive control, cytosine was also conserved at the same positions (À896, À856 and À692) (Figure 4a ), indicating that these sites are methylated, in agreement with previous studies. 23 In contrast, DNA from the normal prostate epithelial cell line, 1542NP, used as a negative control, was not methylated at the positions À896 and À856. This suggests that methylation at these sites is cancer specific and not an artefact due to cell culture (Table 3) .
In all samples, the cytosine residues that were not part of a CG site were converted to thymine by sodium bisulphite modification, confirming successful modification.
Cytosine methylation was also seen at two other sites (À471 and À377) in LNCaP and DU145. The sequence for PC3 DNA at these sites could not be reliably interpreted.
There is a CpG island in the p21 WAF1/CIP1 gene promoter downstream of the sites discussed. The following sites were sequenced in LNCaP and DU145 cell line DNA after modification and were not methylated: À278, À259, À251, À245, À206, À192, À172, À152, À149, À123, À114, À108, À104, À101, À99, À91, À87 and À78.
Discussion
Seven CDKIs have been identified and have been subclassified into two classes on the basis of their structure and their CDK target. 24 The first class, the INK4 proteins, inhibit CDK4 and CDK6 and include p15 INK4b , p16 INK4a , p18 and p19. [25] [26] [27] The second class of CDKIs are the Cip/Kip family, which includes p21
, p27
Kip1 and p57 1,2,28 and they regulate the cyclin D-, E-and A-dependent kinases. 24 Altered expression of CDKIs has been associated with prostate cancer. p27
KIP1 is frequently lost in advanced prostate cancer, 29 and is associated with higher grade disease.
30,31
p16 INK4a is mutated in advanced and metastatic prostate cancer. 32 The pivotal role of CDKIs and in particular p21 WAF1/CIP1 in control of the cell cycle and as a modulator of apoptosis and differentiation implies a tumour suppressor function. 12, 13 The aim of this study was to assess the expression of p21 WAF1/CIP1 in metastatic prostatic cell lines and to determine if the low levels of expression observed result from methylation of the p21 promoter. p21 WAF1/CIP1 gene expression was low or undetectable in the metastatic prostate cancer cell lines and the RD control, but was highly expressed in the normal prostate epithelial cell line (1542NP). Following treatment with the demethylating agent, 5-Aza-CdR, p21 WAF1/CIP1 was re-expressed in the prostate cancer cell lines. This suggests p21 WAF1/CIP1 expression is inactivated by DNA methylation in the prostate cancer cell lines. Low levels of expression were observed in PC3-, LNCaP-and RDuntreated cells, presumably because either methylation is incomplete or because methylation does not completely inhibit gene expression.
SIE-1 sites (TTCNNNGAA) are found at the À692, À2557 and À4232 (SIE-1, SIE-2 and SIE-3, respectively), in the p21 WAF1/CIP1 promoter. STAT1, a cytoplasmic protein which binds to SIE sites, 33 is an essential component of the IFN-g signal transduction pathway. 5 Activation of STAT1 in response to IFN-g results in upregulation of the p21 WAF1/CIP1 gene and inhibition of cell growth. 4, 5 Methylation at the SIE-1-binding site (À692) inhibits binding of STAT1 and decreases p21 WAF1/CIP1 gene expression. 23 The SIE site at À692 was methylated in all three prostate cancer cell lines. Inhibition of STAT binding by methylation may be the mechanism by which the p21 WAF1/CIP1 gene is silenced in prostate cancer cell lines.
CG sites at À896 and À856 were methylated in all three prostate cancer cell lines but not in the normal prostate epithelial cell line, suggesting that methylation at these sites is cancer specific. The CG site at À896 is not a recognised transcription factor-binding site. 34 A myeloid zinc-finger protein MZF1 does bind seven base pairs downstream at À889. 34 MZF-1 is a transcription factor of the Kruppel family of zinc-finger proteins. 35 In in vitro transient transfection experiments, MZF-1 can alter transcription in haemopoietic and nonhaemopoietic cells. 36, 37 It is feasible that methylation close to the MZF-1-binding site alters the structure of the binding domain WAF1/CIP1 gene, suggesting KLF6 is a TSG in prostate cancer. KLF6 interacts with DNA through a GC box promoter element, not in the regions examined in this study. 38 The work by Narla et al 38 on KLF6 does, however, confirm a role for Krupel-like factors in the development and progression of prostate cancer.
Site À856 of the p21 WAF1/CIP1 gene promoter was methylated in all three cancer cell lines and is a transcription factor-binding site. 34 The transcription factor 'cap' binds to sequence TCACTCGT and triggers transcription initiation. 39 The CG at À377 was methylated in LNCaP and DU145 cancer cells and is also a capbinding site, 39 in this instance binding to TCAGCGGT. Little is known about cap in normal or malignant cells.
The 18 CpG sites downstream of the area studied were unmethylated in two cell lines; this implies the p21 WAF1/CIP1 promoter is not inactivated by methylation at these sites. p21 WAF1/CIP1 is one of many cell cycle regulators and fits into the complex pathways of cell cycle control. It may be inactivated in several ways during tumourogenesis and methylation of upstream transcription factors may account for the reactivation of p21 WAF1/CIP1 gene following treatment with 5-Aza-CdR. However, sequencing experiments confirmed several sites on the p21 WAF1/CIP1 promoter were methylated and this suggests inactivation by methylation maybe the mechanism of p21 WAF1/CIP1 inactivation in the cell lines examined.
Further studies are required to examine whether these findings are present in human prostate samples. Results from several preclinical studies have demonstrated that decitabine (5-Aza-CdR) effectively demethylated and reactivated different TSGs in cell lines from breast cancer, mesothelioma, lung, gastric, colorectal cancer and haematological malignancies. The role of decitabine in prostate cancer is under evaluation (NCI-T95-0070). Reactivation of TSGs including p21 WAF1/CIP1 by demethylation may play a role in prostate cancer therapy in the future.
Conclusions
The p21 WAF1/CIP1 gene product has a number of roles involving cell cycle control and apoptosis. With this in mind it is unsurprising that this gene has been implicated as a TSG in a variety of solid and haematological malignancies. This study demonstrates p21 WAF1/CIP1 is poorly expressed in metastatic prostate cancer cell lines and sequestration of the DNA methyltransferase enzyme results in re-expression. Furthermore, several cytosine residues in the promoter region are methylated, in particular the site of STAT1 and cap binding. The inhibition of the STAT1-signalling pathway by methylation of the p21 promoter may inactivate the p21 WAF1/CIP1 TSG in prostate cancer.
